Protagonist Therapeutics to Join Jefferies Global Healthcare Conference 2024
NEWARK, CA – On May 31, 2024, Protagonist Therapeutics, Inc. announced that its President and Chief Executive Officer, Dinesh V. Patel, Ph.D., will join the upcoming Jefferies Global Healthcare Conference in New York City. The conference is scheduled to occur from June 4 to June 6, 2024. Dr. Patel will be engaging in a fireside chat and will conduct one-on-one meetings with attendees.
Conference Details
Event: Jefferies Global Healthcare Conference
Format: Fireside Chat
Date: Wednesday, June 5
Time: 11:00-11:25 A.M. EDT
Location: Track 9
Webcast: A link will be provided for the webcast.
Those interested in private meetings with the Protagonist team are encouraged to contact their Jefferies representative. Additionally, a replay of the fireside chat will be accessible for 90 days on the Events & Presentations section of Protagonist's corporate website.
About Protagonist Therapeutics
Protagonist Therapeutics is a biopharmaceutical firm focused on developing peptide-based new chemical entities (NCEs). Their leading candidates, rusfertide and JNJ-2113 (previously known as PN-235), are in advanced Phase 3 clinical trials. These candidates originate from Protagonist’s proprietary technology platform.
Rusfertide is designed to mimic the natural hormone hepcidin and is the frontrunner in the company’s pipeline. It is currently under a global Phase 3 study called VERIFY, targeting polycythemia vera. This development follows successful Phase 2 trials, with results published in The New England Journal of Medicine in February 2024. The open-label extension of the Phase 2 study continues.
JNJ-2113 emerged from a collaboration between Protagonist and Johnson & Johnson. Discovered as part of their Interleukin-23 receptor (IL-23R) collaboration, this candidate has progressed through IND-enabling pre-clinical and Phase 1 trials. Johnson & Johnson is responsible for its ongoing clinical development.
Collaborations and Partnerships
Protagonist has established significant partnerships to advance its drug candidates. The company works alongside Johnson & Johnson for the development of JNJ-2113. For rusfertide, they have a global co-development and co-commercialization agreement with Takeda Pharmaceutical Company, announced in January 2024.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
